{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T10:18:15Z","timestamp":1788171495871,"version":"build-2803163510"},"reference-count":191,"publisher":"BioExcel","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DIC"],"abstract":"<jats:p>Medullary thyroid carcinoma (MTC) is a rare thyroid malignancy, representing approximately 2\u20135% of all thyroid cancers. It develops from the parafollicular C cells of the thyroid gland. Calcitonin, produced by parafollicular C cells, is a highly reliable biomarker for both diagnosis and disease monitoring. MTC commonly spreads to cervical lymph nodes and can also lead to distant metastases. Approximately 25% of MTC cases are hereditary, occurring as part of multiple endocrine neoplasia syndromes. Inherited forms are driven by germline mutations in the RET proto-oncogene. Genetic testing enables identification of RET carriers, whilst the risk associated with specific RET variants helps determine the optimal timing for prophylactic or therapeutic surgery. Surgical management remains the cornerstone treatment for MTC. Nevertheless, recurrent or metastatic disease continues to pose therapeutic challenges, requiring individualized strategies such as locoregional interventions, radiotherapy and systemic therapies. Tyrosine kinase inhibitors, along with selective RET inhibitors, represent the main therapeutic strategies for patients whose tumours show rapid progression. This review summarizes current surgical, locoregional and systemic treatment strategies for sporadic and hereditary MTC, focusing on the role of multi-kinase and selective RET inhibitors.\n\nDownload the Plain Language Summary of this article: https:\/\/www.drugsincontext.com\/plain-language-summaries\/plain-language-summary-how-to-manage-medullary-thyroid-carcinoma-current-treatment-strategies\n\nThis article is part of the How to manage thyroid diseases: from autoimmunity to malignancy Special Issue: https:\/\/www.drugsincontext.com\/special_issues\/how-to-manage-thyroid-diseases-from-autoimmunity-to-malignancy<\/jats:p>","DOI":"10.7573\/dic.2026-4-3","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T09:56:04Z","timestamp":1788170164000},"page":"1","source":"Crossref","is-referenced-by-count":0,"title":["How to manage medullary thyroid carcinoma: current treatment strategies"],"prefix":"10.7573","author":[{"given":"Katerina","family":"Saltiki","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04gnjpq42","id-type":"ROR","asserted-by":"publisher"}],"name":"National and Kapodistrian University of Athens"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Karapanou","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00y1kmp77","id-type":"ROR","asserted-by":"publisher"}],"name":"NIMTS Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Michalaki","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/017wvtq80","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Patras"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grigoris","family":"Effraimidis","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04v4g9h31","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Thessaly"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10047","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1.\tSiegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7\u201334. https:\/\/doi.org\/10.3322\/ caac.21551","DOI":"10.3322\/caac.21551"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.\tAlevizaki M, Saltiki K, Rentziou G, et al. Medullary thyroid carcinoma: the influence of policy changing in clinical characteristics and disease progression. Eur J Endocrinol. 2012;167(6):799\u2013808. https:\/\/doi.org\/10.1530\/EJE-12-0388","DOI":"10.1530\/EJE-12-0388"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.\tElisei R, Bottici V, Luchetti F, et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab. 2004;89(1):163\u2013168. https:\/\/doi.org\/10.1210\/jc.2003-030550","DOI":"10.1210\/jc.2003-030550"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.\tValle LA, Kloos RT. The prevalence of occult medullary thyroid carcinoma at autopsy. J Clin Endocrinol Metab. 2011;96(1):E109-E113. https:\/\/doi.org\/10.1210\/jc.2010-0959","DOI":"10.1210\/jc.2010-0959"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5.\tScheuba C, Kaserer K, Bieglmayer C, et al. Medullary thyroid microcarcinoma recommendations for treatment \u2013 a single-center experience. Surgery. 2007;142(6):1003\u20131010; discussion 1010.e1-3. https:\/\/doi.org\/10.1016\/ j.surg.2007.09.016","DOI":"10.1016\/j.surg.2007.09.016"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.\tWells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567\u2013610. https:\/\/doi.org\/10.1089\/thy.2014.0335","DOI":"10.1089\/thy.2014.0335"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.\tPacini F, Basolo F, Elisei R, Fugazzola L, Cola A, Pinchera A. Medullary thyroid cancer. An immunohistochemical and humoral study using six separate antigens. Am J Clin Pathol. 1991;95(3):300\u2013308. https:\/\/doi.org\/10.1093\/ajcp\/95.3.300","DOI":"10.1093\/ajcp\/95.3.300"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8.\tFuchs TL, Nassour AJ, Glover A, et al. A proposed grading scheme for medullary thyroid carcinoma based on proliferative activity (Ki-67 and mitotic count) and coagulative necrosis. Am J Surg Pathol. 2020;44(10):1419\u20131428. https:\/\/doi.org\/10.1097\/PAS.0000000000001505","DOI":"10.1097\/PAS.0000000000001505"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9.\tXu B, Fuchs TL, Ahmadi S, et al. International medullary thyroid carcinoma grading system: a validated grading system for medullary thyroid carcinoma. J Clin Oncol. 2022;40(1):96\u2013104. https:\/\/doi.org\/10.1200\/jco.21.01329","DOI":"10.1200\/JCO.21.01329"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.\tKesby N, Mechera R, Fuchs T, et al. Natural history and predictive factors of outcome in medullary thyroid microcarcinoma. J Clin Endocrinol Metab. 2023;108(10):2626\u20132634. https:\/\/doi.org\/10.1210\/clinem\/dgad173","DOI":"10.1210\/clinem\/dgad173"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11.\tMathiesen JS, Effraimidis G, Rossing M, et al. Multiple endocrine neoplasia type 2: a review. Semin Cancer Biol. 2022;79:163\u2013179. https:\/\/doi.org\/10.1016\/j.semcancer.2021.03.035","DOI":"10.1016\/j.semcancer.2021.03.035"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.\tElisei R, Bottici V, Cappagli V, et al. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma. Ann Endocrinol. 2019;80(3):187\u2013190. https:\/\/doi.org\/10.1016\/j.ando.2019.04.014","DOI":"10.1016\/j.ando.2019.04.014"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13.\tTate JG, Bamford S, Jubb HC, et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2019;47(D1):D941\u2013D947. https:\/\/doi.org\/10.1093\/nar\/gky1015","DOI":"10.1093\/nar\/gky1015"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14.\tFrank-Raue K, Raue F. Hereditary medullary thyroid cancer: genotype-phenotype correlation. Recent Results Cancer Res. 2025;223:183\u2013209. https:\/\/doi.org\/10.1007\/978-3-031-80396-3_7","DOI":"10.1007\/978-3-031-80396-3_7"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15.\tElisei R, Romei C, Renzini G, et al. The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single center. J Clin Endocrinol Metab. 2012;97(2):426\u2013435. https:\/\/doi.org\/10.1210\/jc.2011-2046","DOI":"10.1210\/jc.2011-2046"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16.\tPrete A, Matrone A, Romei C, et al. Calcitonin thresholds for prediction of medullary thyroid carcinoma and its clinical response in MEN2A gene carriers. J Clin Endocrinol Metab. 2026;111(7):e1785-e1794. https:\/\/doi.org\/10.1210\/ clinem\/dgag041","DOI":"10.1210\/clinem\/dgag041"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17.\tKebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88(5):1139\u20131148. https:\/\/doi.org\/ 10.1002\/(sici)1097-0142(20000301)88:5<1139::aid-cncr26>3.0.co;2-z","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1139::AID-CNCR26>3.0.CO;2-Z"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18.\tVerbeek HH, Meijer JA, Zandee WT, et al. Fewer cancer reoperations for medullary thyroid cancer after initial surgery according to ATA guidelines. Ann Surg Oncol. 2015;22(4):1207\u20131213. https:\/\/doi.org\/10.1245\/s10434-014-4115-6","DOI":"10.1245\/s10434-014-4115-6"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19.\tSaltiki K, Rentziou G, Stamatelopoulos K, et al. Small medullary thyroid carcinoma: post-operative calcitonin rather than tumour size predicts disease persistence and progression. Eur J Endocrinol. 2014;171(1):117\u2013126. https:\/\/doi.org\/ 10.1530\/eje-14-0076","DOI":"10.1530\/EJE-14-0076"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20.\tRoman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006;107(9):2134\u20132142. https:\/\/doi.org\/10.1002\/cncr.22244","DOI":"10.1002\/cncr.22244"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21.\tWells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30(2):134\u2013141. https:\/\/doi.org\/10.1200\/ jco.2011.35.5040","DOI":"10.1200\/JCO.2011.35.5040"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22.\tElisei R, Schlumberger MJ, Muller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31(29):3639\u20133646. https:\/\/doi.org\/10.1200\/jco.2012.48.4659","DOI":"10.1200\/JCO.2012.48.4659"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"23.\tHadoux J, Elisei R, Brose MS, et al. Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer. N Engl J Med. 2023;389(20):1851\u20131861. https:\/\/doi.org\/10.1056\/NEJMoa2309719","DOI":"10.1056\/NEJMoa2309719"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"24.\tSubbiah V, Hu MI, Wirth LJ, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study. Lancet Diabetes Endocrinol. 2021;9(8):491\u2013501. https:\/\/doi.org\/10.1016\/s2213-8587(21)00120-0","DOI":"10.1016\/S2213-8587(21)00120-0"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25.\tMachens A, Schneyer U, Holzhausen HJ, Dralle H. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab. 2005;90(4):2029\u20132034. https:\/\/doi.org\/10.1210\/ jc.2004-1836","DOI":"10.1210\/jc.2004-1836"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"26.\tScollo C, Baudin E, Travagli JP, et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2003;88(5):2070\u20132075. https:\/\/doi.org\/10.1210\/jc.2002- 021713","DOI":"10.1210\/jc.2002-021713"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"27.\tVuong HG, Le MK, Hassell L, Kondo T, Kakudo K. The differences in distant metastatic patterns and their corresponding survival between thyroid cancer subtypes. Head Neck. 2022;44(4):926\u2013932. https:\/\/doi.org\/10.1002\/ hed.26987","DOI":"10.1002\/hed.26987"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"28.\tBarbosa SL, Rodien P, Leboulleux S, et al. Ectopic adrenocorticotropic hormone-syndrome in medullary carcinoma of the thyroid: a retrospective analysis and review of the literature. Thyroid. 2005;15(6):618\u2013623. https:\/\/doi.org\/ 10.1089\/thy.2005.15.618","DOI":"10.1089\/thy.2005.15.618"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"29.\tMatrone A, Gambale C, Torregrossa L, et al. Comparison of pre-operative calcitonin, FNAC, and ultrasound risk stratification systems in patients with medullary thyroid carcinoma. J Endocrinol Invest. 2026. https:\/\/doi.org\/ 10.1007\/s40618-026-02846-y","DOI":"10.1007\/s40618-026-02846-y"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"30.\tWorkman AD, Soylu S, Kamani D, et al. Limitations of preoperative cytology for medullary thyroid cancer: proposal for improved preoperative diagnosis for optimal initial medullary thyroid carcinoma specific surgery. Head Neck. 2021;43(3):920\u2013927. https:\/\/doi.org\/10.1002\/hed.26550","DOI":"10.1002\/hed.26550"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"31.\tTrimboli P, Treglia G, Guidobaldi L, et al. Detection rate of FNA cytology in medullary thyroid carcinoma: a meta-analysis. Clin Endocrinol. 2015;82(2):280\u2013285. https:\/\/doi.org\/10.1111\/cen.12563","DOI":"10.1111\/cen.12563"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"32.\tMatrone A, Gambale C, Biagini M, Prete A, Vitti P, Elisei R. Ultrasound features and risk stratification systems to identify medullary thyroid carcinoma. Eur J Endocrinol. 2021;185(2):193\u2013200. https:\/\/doi.org\/10.1530\/eje-21-0313","DOI":"10.1530\/EJE-21-0313"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"33.\tFerrarazzo G, Camponovo C, Deandrea M, Piccardo A, Scappaticcio L, Trimboli P. Suboptimal accuracy of ultrasound and ultrasound-based risk stratification systems in detecting medullary thyroid carcinoma should not be overlooked. Findings from a systematic review with meta-analysis. Clin Endocrinol. 2022;97(5):532\u2013540. https:\/\/ doi.org\/10.1111\/cen.14739","DOI":"10.1111\/cen.14739"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"34.\tElisei R, Alevizaki M, Conte-Devolx B, Frank-Raue K, Leite V, Williams GR. 2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer. Eur Thyroid J. 2013;1(4):216\u2013231. https:\/\/doi.org\/10.1159\/000346174","DOI":"10.1159\/000346174"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"35.\tDaniels GH. Screening for medullary thyroid carcinoma with serum calcitonin measurements in patients with thyroid nodules in the United States and Canada. Thyroid. 2011;21(11):1199\u20131207. https:\/\/doi.org\/10.1089\/ thy.2010.0297","DOI":"10.1089\/thy.2010.0297"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"36.\tFiletti S, Durante C, Hartl DM, et al. ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. Ann Oncol. 2022;33(7):674\u2013684. https:\/\/doi.org\/10.1016\/j.annonc.2022.04.009","DOI":"10.1016\/j.annonc.2022.04.009"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"37.\tTrimboli P, Giannelli J, Marques B, Piccardo A, Crescenzi A, Deandrea M. Head-to-head comparison of FNA cytology vs. calcitonin measurement in FNA washout fluids (FNA-CT) to diagnose medullary thyroid carcinoma. A systematic review and meta-analysis. Endocrine. 2022;75(1):33\u201339. https:\/\/doi.org\/10.1007\/s12020-021-02892-x","DOI":"10.1007\/s12020-021-02892-x"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"38.\tKwon H, Kim WG, Choi YM, et al. A cut-off value of basal serum calcitonin for detecting macroscopic medullary thyroid carcinoma. Clin Endocrinol. 2015;82(4):598\u2013603. https:\/\/doi.org\/10.1111\/cen.12562","DOI":"10.1111\/cen.12562"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"39.\tTrimboli P, Seregni E, Treglia G, Alevizaki M, Giovanella L. Procalcitonin for detecting medullary thyroid carcinoma: a systematic review. Endocr Relat Cancer. 2015;22(3):R157-64. https:\/\/doi.org\/10.1530\/erc-15-0156","DOI":"10.1530\/ERC-15-0156"},{"key":"ref39","unstructured":"40.\tKaragiannis AK, Girio-Fragkoulakis C, Nakouti T. Procalcitonin: a new biomarker for medullary thyroid cancer? A systematic review. Anticancer Res. 2016;36(8):3803\u20133810."},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"41.\tGiovanella L, Crippa S, Cariani L. Serum calcitonin-negative medullary thyroid carcinoma: role of CgA and CEA as complementary markers. Int J Biol Markers. 2008;23(2):129\u2013131. https:\/\/doi.org\/10.1177\/172460080802300212","DOI":"10.5301\/JBM.2008.5340"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"42.\tDanila R, Livadariu R, Branisteanu D. Calcitonin revisited in 2020. Acta Endocrinol. 2019;15(4):544\u2013548. https:\/\/ doi.org\/10.4183\/aeb.2019.544","DOI":"10.4183\/aeb.2019.544"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"43.\tTrimboli P, Mian C, Piccardo A, Treglia G. Diagnostic tests for medullary thyroid carcinoma: an umbrella review. Endocrine. 2023;81(2):183\u2013193. https:\/\/doi.org\/10.1007\/s12020-023-03326-6","DOI":"10.1007\/s12020-023-03326-6"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"44.\tde Groot JW, Kema IP, Breukelman H, et al. Biochemical markers in the follow-up of medullary thyroid cancer. Thyroid. 2006;16(11):1163\u20131170. https:\/\/doi.org\/10.1089\/thy.2006.16.1163","DOI":"10.1089\/thy.2006.16.1163"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"45.\tCensi S, Galuppini F, Clausi C, et al. Tumor grade and molecular characteristics associated with survival in sporadic medullary thyroid carcinoma. Thyroid. 2024;34(2):177\u2013185. https:\/\/doi.org\/10.1089\/thy.2023.0482","DOI":"10.1089\/thy.2023.0482"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"46.\tPrete A, Torregrossa L, Gambale C, et al. The usefulness of the international grading system in the management of sporadic medullary thyroid carcinoma. Thyroid. 2025;35(4):387\u2013396. https:\/\/doi.org\/10.1089\/thy.2024.0444","DOI":"10.1089\/thy.2024.0444"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"47.\tAksoy YA, Xu B, Viswanathan K, et al. Novel prognostic nomogram for predicting recurrence-free survival in medullary thyroid carcinoma. Histopathology. 2024;84(6):947\u2013959. https:\/\/doi.org\/10.1111\/his.15141","DOI":"10.1111\/his.15141"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"48.\tNigam A, Mederos MA, Aksoy YA, et al. Multifocality in sporadic medullary thyroid carcinoma is associated with low tumor grade and no difference in somatic driver mutations or overall survival when compared with unifocal tumors. Surgery. 2026;189:109764. https:\/\/doi.org\/10.1016\/j.surg.2025.109764","DOI":"10.1016\/j.surg.2025.109764"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"49.\tTakahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell. 1985;42(2):581\u2013588. https:\/\/doi.org\/10.1016\/0092-8674(85)90115-1","DOI":"10.1016\/0092-8674(85)90115-1"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"50.\tMachens A, Lorenz K, Sekulla C, et al. Molecular epidemiology of multiple endocrine neoplasia 2: implications for RET screening in the new millenium. Eur J Endocrinol. 2013;168(3):307\u2013314. https:\/\/doi.org\/10.1530\/eje-12-0919","DOI":"10.1530\/EJE-12-0919"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"51.\tRomei C, Mariotti S, Fugazzola L, et al. Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. Eur J Endocrinol. 2010;163(2):301\u2013388. https:\/\/doi.org\/10.1530\/eje-10-0333","DOI":"10.1530\/EJE-10-0333"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"52.\tElisei R, Cosci B, Romei C, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab. 2008;93(3):682\u2013687. https:\/\/doi.org\/10.1210\/ jc.2007-1714","DOI":"10.1210\/jc.2007-1714"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"53.\tMian C, Pennelli G, Barollo S, et al. Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification. Eur J Endocrinol. 2011;164(6):971\u2013976. https:\/\/doi.org\/10.1530\/eje-11-0079","DOI":"10.1530\/EJE-11-0079"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"54.\tSpinelli C, Di Giacomo M, Costanzo S, Elisei R, Miccoli P. Role of RET codonic mutations in the surgical management of medullary thyroid carcinoma in pediatric age multiple endocrine neoplasm type 2 syndromes. J Pediatr Surg. 2010;45(8):1610\u20131616. https:\/\/doi.org\/10.1016\/j.jpedsurg.2010.03.019","DOI":"10.1016\/j.jpedsurg.2010.03.019"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"55.\tJuez LD, Mercader E, Amunategui I, Febrero B, Rodr\u00edguez JM, G\u00f3mez-Ram\u00edrez J. Extension of prophylactic surgery in medullary thyroid carcinoma. Differences between sporadic and hereditary tumours according to calcitonin levels and lymph node involvement. World J Surg. 2022;46(4):820\u2013828. https:\/\/doi.org\/10.1007\/s00268-022- 06448-6","DOI":"10.1007\/s00268-022-06448-6"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"56.\tPrete A, Matrone A, Gambale C, et al. Active surveillance in RET gene carriers belonging to families with multiple endocrine Neoplasia. Cancers. 2021;13(21):5554. https:\/\/doi.org\/10.3390\/cancers13215554","DOI":"10.3390\/cancers13215554"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"57.\tKuhlen M, Fr\u00fchwald MC, Dunstheimer DPA, Vorwerk P, Redlich A. Revisiting the genotype-phenotype correlation in children with medullary thyroid carcinoma: a report from the GPOH-MET registry. Pediatr Blood Cancer. 2020;67(4):e28171. https:\/\/doi.org\/10.1002\/pbc.28171","DOI":"10.1002\/pbc.28171"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"58.\tEng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996;276(19):1575\u20131579.","DOI":"10.1001\/jama.1996.03540190047028"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"59.\tShepet K, Alhefdhi A, Lai N, Mazeh H, Sippel R, Chen H. Hereditary medullary thyroid cancer: age-appropriate thyroidectomy improves disease-free survival. Ann Surg Oncol. 2013;20(5):1451\u20131455. https:\/\/doi.org\/10.1245\/s10434- 012-2757-9","DOI":"10.1245\/s10434-012-2757-9"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"60.\tDralle H, Brandenburg T, Weber F, et al. Sporadic noninvasive medullary thyroid neoplasm: a desmoplasia-negative unifocal nonmetastatic tumor cured by hemithyroidectomy. Surgery. 2023;174(6):1356\u20131362. https:\/\/ doi.org\/10.1016\/j.surg.2023.09.003","DOI":"10.1016\/j.surg.2023.09.003"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"61.\tMachens A, Kaatzsch P, Lorenz K, et al. Abandoning node dissection for desmoplasia-negative encapsulated unifocal sporadic medullary thyroid cancer. Surgery. 2022;171(2):360\u2013367. https:\/\/doi.org\/10.1016\/j. surg.2021.07.035","DOI":"10.1016\/j.surg.2021.07.035"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"62.\tLugaresi M, Moneta C, Saruggia G, Dionigi G, Gazzano G, Fugazzola L. Changing the paradigm: lobectomy for sporadic medullary thyroid cancer. European Thyroid J. 2025;14(2):e250040. https:\/\/doi.org\/10.1530\/etj-25-0040","DOI":"10.1530\/ETJ-25-0040"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"63.\tRossi L, Matrone A, Torregrossa L, et al. Highly-selected sporadic, apparently unifocal cN0 MTC may benefit from unilateral surgery. A proof of concept in a high-volume institution. Surgery. 2026;189:109699. https:\/\/doi.org\/10.1016\/ j.surg.2025.109699","DOI":"10.1016\/j.surg.2025.109699"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"64.\tShi X, Shen C, Liu C, et al. Hemithyroidectomy versus total thyroidectomy for sporadic medullary thyroid cancer: a chinese nationwide large-scale cohort study. J Natl Compr Canc Netw. 2025;23(3):105\u2013112. https:\/\/doi.org\/10.6004\/ jnccn.2024.7088","DOI":"10.6004\/jnccn.2024.7088"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"65.\tCohen O, Tzelnick S, Randolph G, et al. Initial surgical management of sporadic medullary thyroid cancer: Guidelines based optimal care \u2013 a systematic review. Clin Endocrinol. 2024;100(5):468\u2013476. https:\/\/doi.org\/10.1111\/cen.15041","DOI":"10.1111\/cen.15041"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"66.\tMao YV, Hughes EG, Steinmetz D, et al. Extent of surgery for medullary thyroid cancer and prevalence of occult contralateral foci. JAMA Otolaryngol Head Neck Surg. 2024;150(3):209\u2013214. https:\/\/doi.org\/10.1001\/ jamaoto.2023.4376","DOI":"10.1001\/jamaoto.2023.4376"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"67.\tMachens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab. 2010;95(6):2655\u20132663. https:\/\/doi.org\/10.1210\/jc.2009-2368","DOI":"10.1210\/jc.2009-2368"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"68.\tMachens A, Ukkat J, Hauptmann S, Dralle H. Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis. Arch Surg. 2007;142(3):289\u2013293; discussion 294. https:\/\/doi.org\/10.1001\/ archsurg.142.3.289","DOI":"10.1001\/archsurg.142.3.289"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"69.\tKuo EJ, Sho S, Li N, Zanocco KA, Yeh MW, Livhits MJ. Risk factors associated with reoperation and disease-specific mortality in patients with medullary thyroid carcinoma. JAMA Surg. 2018;153(1):52\u201359. https:\/\/doi.org\/10.1001\/ jamasurg.2017.3555","DOI":"10.1001\/jamasurg.2017.3555"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"70.\tMiyauchi A, Matsuzuka F, Hirai K, et al. Prospective trial of unilateral surgery for nonhereditary medullary thyroid carcinoma in patients without germline RET mutations. World J Surg. 2002;26(8):1023\u20131028. https:\/\/doi.org\/ 10.1007\/s00268-002-6665-1","DOI":"10.1007\/s00268-002-6665-1"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"71.\tCastinetti F, Qi XP, Walz MK, et al. Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study. Lancet Oncol. 2014;15(6):648\u2013655. https:\/\/doi.org\/10.1016\/s1470-2045(14)70154-8","DOI":"10.1530\/endoabs.37.S12.3"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"72.\tAlevizaki M, Saltiki K. Primary hyperparathyroidism in MEN2 syndromes. Recent Results Cancer Res. 2015;204:179\u2013186. https:\/\/doi.org\/10.1007\/978-3-319-22542-5_8","DOI":"10.1007\/978-3-319-22542-5_8"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"73.\tKebebew E, Greenspan FS, Clark OH, Woeber KA, Grunwell J. Extent of disease and practice patterns for medullary thyroid cancer. J Am Coll Surg. 2005;200(6):890\u2013896. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2004.12.011","DOI":"10.1016\/j.jamcollsurg.2004.12.011"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"74.\tModigliani E, Cohen R, Campos JM, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d\u2019etude des tumeurs a calcitonine. Clin Endocrinol. 1998;48(3):265\u2013273. https:\/\/doi.org\/10.1046\/j.1365-2265.1998.00392.x","DOI":"10.1046\/j.1365-2265.1998.00392.x"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"75.\tBergholm U, Bergstrom R, Ekbom A. Long-term follow-up of patients with medullary carcinoma of the thyroid. Cancer. 1997;79(1):132\u2013138. https:\/\/doi.org\/10.1002\/(sici)1097-0142(19970101)79:1<132::aid-cncr19>3.0.co;2-5","DOI":"10.1002\/(SICI)1097-0142(19970101)79:1<132::AID-CNCR19>3.0.CO;2-5"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"76.\tMathiesen JS, Kroustrup JP, Vestergaard P, et al. Survival and long-term biochemical cure in medullary thyroid carcinoma in Denmark 1997\u20132014: a nationwide study. Thyroid. 2019;29(3):368\u2013377. https:\/\/doi.org\/10.1089\/thy.2018.0564","DOI":"10.1089\/thy.2018.0564"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"77.\tSaltiki K, Simeakis G, Anagnostou E, Zapanti E, Anastasiou E, Alevizaki M. Different outcomes in sporadic versus familial medullary thyroid cancer. Head Neck. 2019;41(1):154\u2013161. https:\/\/doi.org\/10.1002\/hed.25463","DOI":"10.1002\/hed.25463"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"78.\tCaill\u00e9 S, Debreuve-Theresette A, Vitellius G, Deguelte S, La Manna L, Zalzali M. Medullary thyroid cancer: epidemiology and characteristics according to data from the marne-ardennes register 1975\u20132018. J Endocr Soc. 2024;8(6):bvae084. https:\/\/doi.org\/10.1210\/jendso\/bvae084","DOI":"10.1210\/jendso\/bvae084"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"79.\tRaue F, Bruckner T, Frank-Raue K. Similar stage-dependent survival and outcome in sporadic and hereditary medullary thyroid carcinoma. J Clin Endocrinol Metab. 2021;106(9):e3582\u2013e3591. https:\/\/doi.org\/10.1210\/clinem\/dgab326","DOI":"10.1210\/clinem\/dgab326"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"80.\tBarbet J, Campion L, Kraeber-Bodere F, Chatal JF. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2005;90(11):6077\u2013 6084. https:\/\/doi.org\/10.1210\/jc.2005-0044","DOI":"10.1210\/jc.2005-0044"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"81.\tSiironen P, Hagstrom J, Maenpaa HO, Louhimo J, Arola J, Haglund C. Lymph node metastases and elevated postoperative calcitonin: predictors of poor survival in medullary thyroid carcinoma. Acta Oncol. 2016;55(3):357\u2013 364. https:\/\/doi.org\/10.3109\/0284186x.2015.1070963","DOI":"10.3109\/0284186X.2015.1070963"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"82.\tCho YY, Jang HW, Jang JY, et al. Clinical outcomes of patients with hypercalcitoninemia after initial treatment for medullary thyroid cancer and postoperative serum calcitonin cutoffs for predicting structural recurrence. Head Neck. 2016;38(10):1501\u20131508. https:\/\/doi.org\/10.1002\/hed.24469","DOI":"10.1002\/hed.24469"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"83.\tDuval M, Ferreira CV, Marmitt L, et al. An Undetectable postoperative calcitonin level is associated with long-term disease-free survival in medullary thyroid carcinoma: results of a retrospective cohort study. Thyroid. 2023;33(1):82\u201390. https:\/\/doi.org\/10.1089\/thy.2022.0295","DOI":"10.1089\/thy.2022.0295"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"84.\tFanget F, Demarchi MS, Maillard L, Lintis A, Decaussin M, Lifante JC. Medullary thyroid cancer outcomes in patients with undetectable versus normalized postoperative calcitonin levels. Br J Surg. 2021;108(9):1064\u20131071. https:\/\/ doi.org\/10.1093\/bjs\/znab106","DOI":"10.1093\/bjs\/znab106"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"85.\tPrete A, Gambale C, Torregrossa L, et al. Clinical evolution of sporadic medullary thyroid carcinoma with biochemical incomplete response after initial treatment. J Clin Endocrinol Metab. 2023;108(8):e613\u2013e622. https:\/\/ doi.org\/10.1210\/clinem\/dgad061","DOI":"10.1210\/clinem\/dgad061"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"86.\tGiraudet AL, Vanel D, Leboulleux S, et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab. 2007;92(11):4185\u20134190. https:\/\/doi.org\/10.1210\/jc.2007-1211","DOI":"10.1210\/jc.2007-1211"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"87.\tWells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567\u2013610. https:\/\/doi.org\/10.1089\/thy.2014.0335","DOI":"10.1089\/thy.2014.0335"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"88.\tGiovanella L, Deandreis D, Vrachimis A, Campenni A, Petranovic Ovcaricek P. Molecular imaging and theragnostics of thyroid cancers. Cancers. 2022;14(5):1272. https:\/\/doi.org\/10.3390\/cancers14051272","DOI":"10.3390\/cancers14051272"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"89.\tYeh T, Yeung M, Sherman EJ, Tuttle RM, Sabra MM. Structural doubling time predicts overall survival in patients with medullary thyroid cancer in patients with rapidly progressive metastatic medullary thyroid cancer treated with molecular targeted therapies. Thyroid. 2020;30(8):1112\u20131119. https:\/\/doi.org\/10.1089\/thy.2019.0579","DOI":"10.1089\/thy.2019.0579"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"90.\tGiovanella L, Treglia G, Iakovou I, Mihailovic J, Verburg FA, Luster M. EANM practice guideline for PET\/CT imaging in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2020;47(1):61\u201377. https:\/\/doi.org\/10.1007\/s00259-019- 04458-6","DOI":"10.1007\/s00259-019-04458-6"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"91.\tCastinetti F, Ta\u00efeb D. Positron emission tomography imaging in medullary thyroid carcinoma: time for reappraisal? Thyroid. 2021;31(2):151\u2013155. https:\/\/doi.org\/10.1089\/thy.2020.0674","DOI":"10.1089\/thy.2020.0674"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"92.\tLaure Giraudet A, Al Ghulzan A, Auperin A, et al. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol. 2008;158(2):239\u2013246. https:\/\/doi.org\/ 10.1530\/eje-07-0667","DOI":"10.1530\/EJE-07-0667"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"93.\tMendelsohn G, Wells SA Jr, Baylin SB. Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. An immunohistochemical study in early, localized, and virulent disseminated stages of disease. Cancer. 1984;54(4):657\u2013662. https:\/\/doi.org\/10.1002\/ 1097-0142(1984)54:4<657::aid-cncr2820540412>3.0.co;2-v","DOI":"10.1002\/1097-0142(1984)54:4<657::AID-CNCR2820540412>3.0.CO;2-V"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"94.\tTrimboli P, Lauretta R, Barnabei A, et al. Procalcitonin as a postoperative marker in the follow-up of patients affected by medullary thyroid carcinoma. Int J Biol Markers. 2018;33(2):156\u2013160. https:\/\/doi.org\/10.1177\/ 1724600817747518","DOI":"10.1177\/1724600817747518"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"95.\tLorusso L, Romei C, Piaggi P, et al. Ca19.9 Positivity and doubling time are prognostic factors of mortality in patients with advanced medullary thyroid cancer with no evidence of structural disease progression according to response evaluation criteria in solid tumors. Thyroid. 2021;31(7):1050\u20131055. https:\/\/doi.org\/10.1089\/thy.2020.0060","DOI":"10.1089\/thy.2020.0060"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"96.\tGaluppini F, Censi S, Moro M, et al. MicroRNAs in medullary thyroid carcinoma: a state of the art review of the regulatory mechanisms and future perspectives. Cells. 2021;10(4):955. https:\/\/doi.org\/10.3390\/cells10040955","DOI":"10.3390\/cells10040955"},{"key":"ref96","doi-asserted-by":"crossref","unstructured":"97.\tPapachristos AJ, Nicholls LE, Mechera R, et al. Management of medullary thyroid cancer: patterns of recurrence and outcomes of reoperative surgery. Oncologist. 2023;28(12):1064\u20131071. https:\/\/doi.org\/10.1093\/oncolo\/oyad232","DOI":"10.1093\/oncolo\/oyad232"},{"key":"ref97","doi-asserted-by":"crossref","unstructured":"98.\tLiu CQ, Shen CK, Du YX, et al. Survival outcome and optimal candidates of primary tumor resection for patients with metastatic medullary thyroid cancer. J Clin Endocrinol Metab. 2024;109(11):2979\u20132985. https:\/\/doi.org\/10.1210\/ clinem\/dgae214","DOI":"10.1210\/clinem\/dgae214"},{"key":"ref98","doi-asserted-by":"crossref","unstructured":"99.\tManiakas A, Sullivan A, Hu MI, et al. Decreasing utilization for postoperative radiation therapy in locoregionally advanced medullary thyroid cancer. Head Neck. 2024;46(2):328\u2013335. https:\/\/doi.org\/10.1002\/hed.27584","DOI":"10.1002\/hed.27780"},{"key":"ref99","doi-asserted-by":"crossref","unstructured":"100.\tOw TJ, Mehta V, Kim S, Vakil M, Friedmann P, In H. Evaluation of survival and postoperative radiation among patients with advanced medullary thyroid carcinoma: an analysis of the National Cancer Database. Ann Surg Oncol. 2022;29(4):2582\u20132591. https:\/\/doi.org\/10.1245\/s10434-021-11158-9","DOI":"10.1245\/s10434-021-11158-9"},{"key":"ref100","doi-asserted-by":"crossref","unstructured":"101.\tPuleo L, Agate L, Bargellini I, et al. Yttrium-90 transarterial radioembolization for liver metastases from medullary thyroid cancer. Eur Thyroid J. 2022;11(6):e220130. https:\/\/doi.org\/10.1530\/etj-22-0130","DOI":"10.1530\/ETJ-22-0130"},{"key":"ref101","doi-asserted-by":"crossref","unstructured":"102.\tBonichon F, de Baere T, Berdelou A, et al. Percutaneous thermal ablation of lung metastases from thyroid carcinomas. A retrospective multicenter study of 107 nodules. On behalf of the TUTHYREF network. Endocrine. 2021;72(3):798\u2013808. https:\/\/doi.org\/10.1007\/s12020-020-02580-2","DOI":"10.1007\/s12020-020-02580-2"},{"key":"ref102","doi-asserted-by":"crossref","unstructured":"103.\tSaltiki K, Simeakis G, Karapanou O, Paschou SA, Alevizaki M. Metastatic medullary thyroid carcinoma (MTC): disease course, treatment modalities and factors predisposing for drug resistance. Endocrine. 2023;80(3):570\u2013579. https:\/\/ doi.org\/10.1007\/s12020-022-03296-1","DOI":"10.1007\/s12020-022-03296-1"},{"key":"ref103","doi-asserted-by":"crossref","unstructured":"104.\tKoehler VF, Fuss CT, Berr CM, et al. Medullary thyroid cancer with ectopic Cushing\u2019s syndrome: a multicentre case series. Clin Endocrinol. 2022;96(6):847\u2013856. https:\/\/doi.org\/10.1111\/cen.14617","DOI":"10.1111\/cen.14617"},{"key":"ref104","doi-asserted-by":"crossref","unstructured":"105.\tEfstathiadou ZA, Tsentidis C, Bargiota A, et al. Benefits and limitations of TKIs in patients with medullary thyroid cancer: a systematic review and meta-analysis. Eur Thyroid J. 2021;10(2):125\u2013139. https:\/\/doi. org\/10.1159\/000509457","DOI":"10.1159\/000509457"},{"key":"ref105","doi-asserted-by":"crossref","unstructured":"106.\tHadoux J, Pacini F, Tuttle RM, Schlumberger M. Management of advanced medullary thyroid cancer. Lancet Diabetes Endocrinol. 2016;4(1):64\u201371. https:\/\/doi.org\/10.1016\/s2213-8587(15)00337-x","DOI":"10.1016\/S2213-8587(15)00337-X"},{"key":"ref106","doi-asserted-by":"crossref","unstructured":"107.\tRoskoski R Jr, Sadeghi-Nejad A. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers. Pharmacol Res. 2018;128:1\u201317. https:\/\/doi.org\/10.1016\/j.phrs.2017.12.021","DOI":"10.1016\/j.phrs.2017.12.021"},{"key":"ref107","doi-asserted-by":"crossref","unstructured":"108.\tGild ML, Clifton-Bligh RJ, Wirth LJ, Robinson BG. Medullary thyroid cancer: updates and challenges. Endocr Rev. 2023;44(5):934\u2013946. https:\/\/doi.org\/10.1210\/endrev\/bnad013","DOI":"10.1210\/endrev\/bnad013"},{"key":"ref108","doi-asserted-by":"crossref","unstructured":"109.\tRomei C, Casella F, Tacito A, et al. New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double RET mutations. J Med Genet. 2016;53(11):729\u2013734. https:\/\/ doi.org\/10.1136\/jmedgenet-2016-103833","DOI":"10.1136\/jmedgenet-2016-103833"},{"key":"ref109","doi-asserted-by":"crossref","unstructured":"110.\tCiampi R, Mian C, Fugazzola L, et al. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. Thyroid. 2013;23(1):50\u201357. https:\/\/doi.org\/10.1089\/thy.2012.0207","DOI":"10.1089\/thy.2012.0207"},{"key":"ref110","doi-asserted-by":"crossref","unstructured":"111.\tMoura MM, Cavaco BM, Leite V. RAS proto-oncogene in medullary thyroid carcinoma. Endocr Relat Cancer. 2015;22(5):R235-52. https:\/\/doi.org\/10.1530\/erc-15-0070","DOI":"10.1530\/ERC-15-0070"},{"key":"ref111","doi-asserted-by":"crossref","unstructured":"112.\tXu B, Viswanathan K, Ahadi MS, et al. Association of the Genomic profile of medullary thyroid carcinoma with tumor characteristics and clinical outcomes in an international multicenter study. Thyroid. 2024;34(2):167\u2013176. https:\/\/doi.org\/10.1089\/thy.2023.0279","DOI":"10.1089\/thy.2023.0279"},{"key":"ref112","doi-asserted-by":"crossref","unstructured":"113.\tAl-Jundi M, Thakur S, Gubbi S, Klubo-Gwiezdzinska J. Novel targeted therapies for metastatic thyroid cancer \u2013 a comprehensive review. Cancers. 2020;12(8):2104. https:\/\/doi.org\/10.3390\/cancers12082104","DOI":"10.3390\/cancers12082104"},{"key":"ref113","doi-asserted-by":"crossref","unstructured":"114.\tCiampi R, Romei C, Ramone T, et al. Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing. iScience. 2019;20:324\u2013336. https:\/\/doi.org\/10.1016\/j.isci.2019.09.030","DOI":"10.1016\/j.isci.2019.09.030"},{"key":"ref114","doi-asserted-by":"crossref","unstructured":"115.\tVerbeek HH, Alves MM, de Groot JW, et al. The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells. J Clin Endocrinol Metab. 2011;96(6):E991-E995. https:\/\/doi.org\/10.1210\/jc.2010-2381","DOI":"10.1210\/jc.2010-2381"},{"key":"ref115","doi-asserted-by":"crossref","unstructured":"116.\tFox E, Widemann BC, Chuk MK, et al. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma. Clin Cancer Res. 2013;19(15):4239\u20134248. https:\/\/ doi.org\/10.1158\/1078-0432.ccr-13-0071","DOI":"10.1158\/1078-0432.CCR-13-0071"},{"key":"ref116","unstructured":"117.\tAgrawal N, Jiao Y, Sausen M, et al. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab. 2013;98(2):E364-E369. https:\/\/ doi.org\/10.1210\/jc.2012-2703"},{"key":"ref117","doi-asserted-by":"crossref","unstructured":"118.\tMatrone A, Prete A, Gambale C, Elisei R. Timing and ideal patient for an appropriate search for somatic RET mutation in medullary thyroid cancer. JCO Precis Oncol. 2024;8:e2400017. https:\/\/doi.org\/10.1200\/po.24.00017","DOI":"10.1200\/PO.24.00017"},{"key":"ref118","doi-asserted-by":"crossref","unstructured":"119.\tElisei R, Romei C. Looking for RET alterations in thyroid cancer: clinical relevance, methodology and timing. Endocrine. 2023;81(2):206\u2013215. https:\/\/doi.org\/10.1007\/s12020-023-03368-w","DOI":"10.1007\/s12020-023-03368-w"},{"key":"ref119","doi-asserted-by":"crossref","unstructured":"120.\tPapotti M, Olivero M, Volante M, et al. Expression of hepatocyte growth factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroid. Endocr Pathol. 2000;11(1):19\u201330. https:\/\/doi.org\/10.1385\/ep:11:1:19","DOI":"10.1385\/EP:11:1:19"},{"key":"ref120","doi-asserted-by":"crossref","unstructured":"121.\tPlaza-Menacho I, Mologni L, McDonald NQ. Mechanisms of RET signaling in cancer: current and future implications for targeted therapy. Cell Signal. 2014;26(8):1743\u20131752. https:\/\/doi.org\/10.1016\/j.cellsig.2014.03.032","DOI":"10.1016\/j.cellsig.2014.03.032"},{"key":"ref121","doi-asserted-by":"crossref","unstructured":"122.\tLinks TP, Verbeek HH, Hofstra RM, Plukker JT. Endocrine tumours: progressive metastatic medullary thyroid carcinoma: first- and second-line strategies. Eur J Endocrinol. 2015;172(6):R241-R251. https:\/\/doi.org\/10.1530\/eje-14-0726","DOI":"10.1530\/EJE-14-0726"},{"key":"ref122","doi-asserted-by":"crossref","unstructured":"123.\tSaltiki K, Simeakis G, Karapanou O, Alevizaki M. MANAGEMENT OF ENDOCRINE DISEASE: Medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectives. Eur J Endocrinol. 2022;187(3):R53-R63. https:\/\/doi.org\/10.1530\/eje-22-0312","DOI":"10.1530\/EJE-22-0312"},{"key":"ref123","doi-asserted-by":"crossref","unstructured":"124.\tMatrone A, Gambale C, Prete A, Elisei R. Sporadic medullary thyroid carcinoma: towards a precision medicine. Front Endocrinol. 2022;13:864253. https:\/\/doi.org\/10.3389\/fendo.2022.864253","DOI":"10.3389\/fendo.2022.864253"},{"key":"ref124","doi-asserted-by":"crossref","unstructured":"125.\tWells SA Jr, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010;28(5):767\u2013772. https:\/\/doi.org\/10.1200\/ JCO.2009.23.6604","DOI":"10.1200\/JCO.2009.23.6604"},{"key":"ref125","doi-asserted-by":"crossref","unstructured":"126.\tKreissl MC, Bastholt L, Elisei R, et al. Efficacy and safety of vandetanib in progressive and symptomatic medullary thyroid cancer: post hoc analysis from the ZETA trial. J Clin Oncol. 2020;38(24):2773\u20132781. https:\/\/doi.org\/10.1200\/ jco.19.02790","DOI":"10.1200\/JCO.19.02790"},{"key":"ref126","doi-asserted-by":"crossref","unstructured":"127.\tKim M, Yoon JH, Ahn J, et al. Vandetanib for the management of advanced medullary thyroid cancer: a real-world multicenter experience. Endocrinol Metab. 2020;35(3):587\u2013594. https:\/\/doi.org\/10.3803\/EnM.2020.687","DOI":"10.3803\/EnM.2020.687"},{"key":"ref127","doi-asserted-by":"crossref","unstructured":"128.\tKoehler VF, Adam P, Frank-Raue K, et al. Real-world efficacy and safety of cabozantinib and vandetanib in advanced medullary thyroid cancer. Thyroid. 2021;31(3):459\u2013469. https:\/\/doi.org\/10.1089\/thy.2020.0206","DOI":"10.1089\/thy.2020.0206"},{"key":"ref128","doi-asserted-by":"crossref","unstructured":"129.\tChougnet CN, Borget I, Leboulleux S, et al. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort. Thyroid. 2015;25(4):386\u2013391. https:\/\/doi.org\/10.1089\/ thy.2014.0361","DOI":"10.1089\/thy.2014.0361"},{"key":"ref129","doi-asserted-by":"crossref","unstructured":"130.\tRamos HE, Hecht F, Berdelou A, et al. Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer. Endocrine. 2021;71(2):434\u2013442. https:\/\/doi.org\/10.1007\/s12020-020-02426-x","DOI":"10.1007\/s12020-020-02426-x"},{"key":"ref130","doi-asserted-by":"crossref","unstructured":"131.\tValerio L, Bottici V, Matrone A, et al. Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response. Endocr Relat Cancer. 2020;27(2):97\u2013110. https:\/\/doi.org\/10.1530\/erc-19-0259","DOI":"10.1530\/ERC-19-0259"},{"key":"ref131","doi-asserted-by":"crossref","unstructured":"132.\tFallahi P, Ferrari SM, Galdiero MR, et al. Molecular targets of tyrosine kinase inhibitors in thyroid cancer. Semin Cancer Biol. 2022;79:180\u2013196. https:\/\/doi.org\/10.1016\/j.semcancer.2020.11.013","DOI":"10.1016\/j.semcancer.2020.11.013"},{"key":"ref132","doi-asserted-by":"crossref","unstructured":"133.\tCapdevila J, Klochikhin A, Leboulleux S, et al. A randomized, double-blind noninferiority study to evaluate the efficacy of the cabozantinib tablet at 60 mg per day compared with the cabozantinib capsule at 140 mg per day in patients with progressive, metastatic medullary thyroid cancer. Thyroid. 2022;32(5):515\u2013524. https:\/\/ doi.org\/10.1089\/thy.2022.0027","DOI":"10.1089\/thy.2022.0027"},{"key":"ref133","doi-asserted-by":"crossref","unstructured":"134.\tSchlumberger M, Bastholt L, Dralle H, Jarzab B, Pacini F, Smit JW. 2012 European Thyroid Association guidelines for metastatic medullary thyroid cancer. Eur Thyroid J. 2012;1(1):5\u201314. https:\/\/doi.org\/10.1159\/000336977","DOI":"10.1159\/000336977"},{"key":"ref134","doi-asserted-by":"crossref","unstructured":"135.\tLiu X, Shen T, Mooers BHM, Hilberg F, Wu J. Drug resistance profiles of mutations in the RET kinase domain. Br J Pharmacol. 2018;175(17):3504\u20133515. https:\/\/doi.org\/10.1111\/bph.14395","DOI":"10.1111\/bph.14395"},{"key":"ref135","doi-asserted-by":"crossref","unstructured":"136.\tSubbiah V, Yang D, Velcheti V, Drilon A, Meric-Bernstam F. State-of-the-art strategies for targeting RET-dependent cancers. J Clin Oncol. 2020;38(11):1209\u20131221. https:\/\/doi.org\/10.1200\/jco.19.02551","DOI":"10.1200\/JCO.19.02551"},{"key":"ref136","doi-asserted-by":"crossref","unstructured":"137.\tSalvatore D, Santoro M, Schlumberger M. The importance of the RET gene in thyroid cancer and therapeutic implications. Nat Rev Endocrinol. 2021;17(5):296\u2013306. https:\/\/doi.org\/10.1038\/s41574-021-00470-9","DOI":"10.1038\/s41574-021-00470-9"},{"key":"ref137","doi-asserted-by":"crossref","unstructured":"138.\tCarlomagno F, Guida T, Anaganti S, et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene. 2004;23(36):6056\u20136063. https:\/\/doi.org\/10.1038\/ sj.onc.1207810","DOI":"10.1038\/sj.onc.1207810"},{"key":"ref138","doi-asserted-by":"crossref","unstructured":"139.\tWirth LJ, Sherman E, Robinson B, et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med. 2020;383(9):825\u2013835. https:\/\/doi.org\/10.1056\/NEJMoa2005651","DOI":"10.1056\/NEJMe2024831"},{"key":"ref139","doi-asserted-by":"crossref","unstructured":"140.\tMachlah YM, Srasra LM, Theurer S, et al. Real-world efficacy and safety of selpercatinib in RET-mutant medullary thyroid cancer at a Tertiary Referral Center. Eur J Endocrinol. 2025;193(6):762\u2013771. https:\/\/doi.org\/10.1093\/ejendo\/ lvaf256","DOI":"10.1093\/ejendo\/lvaf256"},{"key":"ref140","doi-asserted-by":"crossref","unstructured":"141.\tSubbiah V, Gainor JF, Rahal R, et al. Precision targeted therapy with BLU-667 for RET-driven cancers. Cancer Discov. 2018;8(7):836\u2013849. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0338","DOI":"10.1158\/2159-8290.CD-18-0338"},{"key":"ref141","doi-asserted-by":"crossref","unstructured":"142.\tSubbiah V, Hu MI, Mansfield AS, et al. Pralsetinib in patients with advanced\/metastatic rearranged during transfection (RET)-altered thyroid cancer: updated efficacy and safety data from the ARROW study. Thyroid. 2024;34(1):26\u201340. https:\/\/doi.org\/10.1089\/thy.2023.0363","DOI":"10.1089\/thy.2023.0363"},{"key":"ref142","doi-asserted-by":"crossref","unstructured":"143.\tZheng X, Fang M, Fan Y, et al. Efficacy and safety of pralsetinib in Chinese advanced RET-mutant medullary thyroid cancer patients. Endocr Relat Cancer. 2024;31(4):e2301344. https:\/\/doi.org\/10.1530\/erc-23-0134","DOI":"10.1530\/ERC-23-0134"},{"key":"ref143","doi-asserted-by":"crossref","unstructured":"144.\tYun KM, Cohen EEW. An era of advances in systemic therapies for advanced thyroid cancer. JCO Oncol Pract. 2024:Op2300747. https:\/\/doi.org\/10.1200\/op.23.00747","DOI":"10.1200\/OP.23.00747"},{"key":"ref144","doi-asserted-by":"crossref","unstructured":"145.\tZhao M, Li R, Song Z, Miao C, Lu J. Efficacy and safety of tyrosine kinase inhibitors for advanced metastatic thyroid cancer: a systematic review and network meta-analysis of randomized controlled trials. Medicine. 2024;103(15):e37655. https:\/\/doi.org\/10.1097\/md.0000000000037655","DOI":"10.1097\/MD.0000000000037655"},{"key":"ref145","doi-asserted-by":"crossref","unstructured":"146.\tCabanillas ME, Ryder M, Jimenez C. Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond. Endocr Rev. 2019;40(6):1573\u20131604. https:\/\/doi.org\/10.1210\/er.2019-00007","DOI":"10.1210\/er.2019-00007"},{"key":"ref146","doi-asserted-by":"crossref","unstructured":"147.\tBible KC, Suman VJ, Molina JR, et al. A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. J Clin Endocrinol Metab. 2014;99(5):1687\u20131693. https:\/\/doi.org\/10.1210\/ jc.2013-3713","DOI":"10.1210\/jc.2013-3713"},{"key":"ref147","doi-asserted-by":"crossref","unstructured":"148.\tSchlumberger M, Jarzab B, Cabanillas ME, et al. A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer. Clin Cancer Res. 2016;22(1):44\u201353. https:\/\/doi.org\/ 10.1158\/1078-0432.ccr-15-1127","DOI":"10.1158\/1078-0432.CCR-15-1127"},{"key":"ref148","doi-asserted-by":"crossref","unstructured":"149.\tLi D, Chi Y, Chen X, et al. Anlotinib in locally advanced or metastatic medullary thyroid carcinoma: a randomized, double-blind phase IIB trial. Clin Cancer Res. 2021;27(13):3567\u20133575. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-2950","DOI":"10.1158\/1078-0432.CCR-20-2950"},{"key":"ref149","doi-asserted-by":"crossref","unstructured":"150.\tLi S, Wang H. Research progress on mechanism and management of adverse drug reactions of anlotinib. Drug Des Devel Ther. 2023;17:3429\u20133437. https:\/\/doi.org\/10.2147\/dddt.S426898","DOI":"10.2147\/DDDT.S426898"},{"key":"ref150","doi-asserted-by":"crossref","unstructured":"151.\tZhao J, Chi Y, Hu C, et al. Anlotinib in patients with medullary thyroid carcinoma with negative prognostic factors: a sub-analysis based on the ALTER01031 study. Front Oncol. 2022;12:852032. https:\/\/doi.org\/10.3389\/fonc.2022.852032","DOI":"10.3389\/fonc.2022.852032"},{"key":"ref151","doi-asserted-by":"crossref","unstructured":"152.\tMatrone A, Prete A, Nervo A, et al. Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer. J Endocrinol Invest. 2021;44(10):2139\u20132151. https:\/\/doi.org\/10.1007\/s40618-020-01491-3","DOI":"10.1007\/s40618-020-01491-3"},{"key":"ref152","doi-asserted-by":"crossref","unstructured":"153.\tRom\u00e1n-Gil MS, Pozas J, Rosero-Rodr\u00edguez D, et al. Resistance to RET targeted therapy in thyroid cancer: molecular basis and overcoming strategies. Cancer Treat Rev. 2022;105:102372. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102372","DOI":"10.1016\/j.ctrv.2022.102372"},{"key":"ref153","doi-asserted-by":"crossref","unstructured":"154.\tSubbiah V, Shen T, Terzyan SS, et al. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Ann Oncol. 2021;32(2):261\u2013268. https:\/\/doi.org\/10.1016\/ j.annonc.2020.10.599","DOI":"10.1016\/j.annonc.2020.10.599"},{"key":"ref154","doi-asserted-by":"crossref","unstructured":"155.\tGambale C, Prete A, Romei C, Celi A, Elisei R, Matrone A. Fluctuating obliterative bronchiolitis in RET-mutant medullary thyroid cancer patient treated with selpercatinib. Eur Thyroid J. 2024;13(5):e240189. https:\/\/doi.org\/ 10.1530\/etj-24-0189","DOI":"10.1530\/ETJ-24-0189"},{"key":"ref155","doi-asserted-by":"crossref","unstructured":"156.\tKalchiem-Dekel O, Falcon CJ, Bestvina CM, et al. Brief report: chylothorax and chylous ascites during RET tyrosine kinase inhibitor therapy. J Thoracic Oncol. 2022;17(9):1130\u20131136. https:\/\/doi.org\/10.1016\/j.jtho.2022.06.008","DOI":"10.1016\/j.jtho.2022.06.008"},{"key":"ref156","doi-asserted-by":"crossref","unstructured":"157.\tMatrone A, Kroiss M, Gild ML, et al. Erectile dysfunction in patients treated with selpercatinib for RET-altered thyroid cancer. Thyroid. 2024;34(9):1177\u20131180. https:\/\/doi.org\/10.1089\/thy.2024.0129","DOI":"10.1089\/thy.2024.0129"},{"key":"ref157","doi-asserted-by":"crossref","unstructured":"158.\tPrete A, Gambale C, Cappagli V, et al. Chylous effusions in advanced medullary thyroid cancer patients treated with selpercatinib. Eur J Endocrinol. 2022;187(6):905\u2013915. https:\/\/doi.org\/10.1530\/eje-22-0643","DOI":"10.1530\/EJE-22-0643"},{"key":"ref158","doi-asserted-by":"crossref","unstructured":"159.\tTsang V, Gill A, Gild M, et al. Selpercatinib treatment of RET-mutated thyroid cancers is associated with gastrointestinal adverse effects. J Clin Endocrinol Metab. 2022;107(9):e3824\u2013e3829. https:\/\/doi.org\/10.1210\/clinem\/ dgac337","DOI":"10.1210\/clinem\/dgac337"},{"key":"ref159","doi-asserted-by":"crossref","unstructured":"160.\tBoucai L, Salas-Lucia F, Krishnamoorthy GP, et al. Selpercatinib-induced hypothyroidism through off-target inhibition of type 2 iodothyronine deiodinase. JCO Precis Oncol. 2022;6:e2100496. https:\/\/doi.org\/10.1200\/ po.21.00496","DOI":"10.1200\/PO.21.00496"},{"key":"ref160","doi-asserted-by":"crossref","unstructured":"161.\tLovly CM, Shaw AT. Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies. Clin Cancer Res. 2014;20(9):2249\u20132256. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-1610","DOI":"10.1158\/1078-0432.CCR-13-1610"},{"key":"ref161","doi-asserted-by":"crossref","unstructured":"162.\tBusaidy NL. The year in medical thyroidology review: current challenges and future directions. Thyroid. 2020;30(1):13\u201319. https:\/\/doi.org\/10.1089\/thy.2019.0792","DOI":"10.1089\/thy.2019.0792"},{"key":"ref162","doi-asserted-by":"crossref","unstructured":"163.\tNakaoku T, Kohno T, Araki M, et al. A secondary RET mutation in the activation loop conferring resistance to vandetanib. Nat Commun. 2018;9(1):625. https:\/\/doi.org\/10.1038\/s41467-018-02994-7","DOI":"10.1038\/s41467-018-02994-7"},{"key":"ref163","doi-asserted-by":"crossref","unstructured":"164.\tSolomon BJ, Tan L, Lin JJ, et al. RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies. J Thorac Oncol. 2020;15(4):541\u2013549. https:\/\/doi.org\/10.1016\/j.jtho.2020.01.006","DOI":"10.1016\/j.jtho.2020.01.006"},{"key":"ref164","doi-asserted-by":"crossref","unstructured":"165.\tPlenker D, Riedel M, Bragelmann J, et al. Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors. Sci Transl Med. 2017;9(394):eaah6144. https:\/\/doi.org\/10.1126\/scitranslmed.aah6144","DOI":"10.1126\/scitranslmed.aah6144"},{"key":"ref165","doi-asserted-by":"crossref","unstructured":"166.\tSubbiah V, Cote GJ. Advances in targeting RET-dependent cancers. Cancer Discov. 2020;10(4):498\u2013505. https:\/\/ doi.org\/10.1158\/2159-8290.Cd-19-1116","DOI":"10.1158\/2159-8290.CD-19-1116"},{"key":"ref166","doi-asserted-by":"crossref","unstructured":"167.\tNelson-Taylor SK, Le AT, Yoo M, et al. Resistance to RET-inhibition in RET-rearranged NSCLC is mediated by reactivation of RAS\/MAPK signaling. Mol Cancer Ther. 2017;16(8):1623\u20131633. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0008","DOI":"10.1158\/1535-7163.MCT-17-0008"},{"key":"ref167","doi-asserted-by":"crossref","unstructured":"168.\tHadoux J, Al Ghuzlan A, Lamartina L, et al. Patterns of treatment failure after selective rearranged during transfection (RET) inhibitors in patients with metastatic medullary thyroid carcinoma. JCO Precis Oncol. 2023;7:e2300053. https:\/\/doi.org\/10.1200\/po.23.00053","DOI":"10.1200\/PO.23.00053"},{"key":"ref168","doi-asserted-by":"crossref","unstructured":"169.\tSaw PE, Chen J, Song E. Targeting CAFs to overcome anticancer therapeutic resistance. Trends Cancer. 2022;8(7):527\u2013555. https:\/\/doi.org\/10.1016\/j.trecan.2022.03.001","DOI":"10.1016\/j.trecan.2022.03.001"},{"key":"ref169","doi-asserted-by":"crossref","unstructured":"170.\tJoo LJS, Weiss J, Gill AJ, et al. RET kinase-regulated microRNA-153-3p improves therapeutic efficacy in medullary thyroid carcinoma. Thyroid. 2019;29(6):830\u2013844. https:\/\/doi.org\/10.1089\/thy.2018.0525","DOI":"10.1089\/thy.2018.0525"},{"key":"ref170","doi-asserted-by":"crossref","unstructured":"171.\tGhafouri-Fard S, Shirvani-Farsani Z, Taheri M. The role of microRNAs in the pathogenesis of thyroid cancer. Non-coding RNA Res. 2020;5(3):88\u201398. https:\/\/doi.org\/10.1016\/j.ncrna.2020.06.001","DOI":"10.1016\/j.ncrna.2020.06.001"},{"key":"ref171","doi-asserted-by":"crossref","unstructured":"172.\tSaha D, Ryan KR, Lakkaniga NR, et al. Targeting rearranged during transfection in cancer: a perspective on small-molecule inhibitors and their clinical development. J Med Chem. 2021;64(16):11747\u201311773. https:\/\/doi.org\/10.1021\/ acs.jmedchem.0c02167","DOI":"10.1021\/acs.jmedchem.0c02167"},{"key":"ref172","doi-asserted-by":"crossref","unstructured":"173.\tHamidi S, Hu MI. RET kinase inhibitors for the treatment of RET-altered thyroid cancers: current knowledge and future directions. Ann Endocrinol. 2024;85(2):118\u2013126. https:\/\/doi.org\/10.1016\/j.ando.2024.02.001","DOI":"10.1016\/j.ando.2024.02.001"},{"key":"ref173","doi-asserted-by":"crossref","unstructured":"174.\tRosen EY, Johnson ML, Clifford SE, et al. Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinib. Clin Cancer Res. 2021;27(1):34\u201342. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-2278","DOI":"10.1158\/1078-0432.CCR-20-2278"},{"key":"ref174","doi-asserted-by":"crossref","unstructured":"175.\tLi Y, Luo Z, Wang X, Zhang S, Hei H, Qin J. Design of new drugs for medullary thyroid carcinoma. Front Oncol. 2022;12:993725. https:\/\/doi.org\/10.3389\/fonc.2022.993725","DOI":"10.3389\/fonc.2022.993725"},{"key":"ref175","doi-asserted-by":"crossref","unstructured":"176.\tMansfield AS, Hong DS, Hann CL, et al. A phase I\/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. NPJ Precis Oncol. 2021;5(1):74. https:\/\/doi.org\/10.1038\/s41698-021-00214-y","DOI":"10.1038\/s41698-021-00214-y"},{"key":"ref176","doi-asserted-by":"crossref","unstructured":"177.\tBagheri-Yarmand R, Dadu R, Ye L, et al. ONC201 shows potent anticancer activity against medullary thyroid cancer via transcriptional inhibition of RET, VEGFR2, and IGFBP2. Mol Cancer Ther. 2021;20(4):665\u2013675. https:\/\/doi.org\/ 10.1158\/1535-7163.Mct-20-0386","DOI":"10.1158\/1535-7163.MCT-20-0386"},{"key":"ref177","doi-asserted-by":"crossref","unstructured":"178.\tRoberts TJ, Meador CB, Fuld AD, et al. A novel approach to targeting DLL3 with tarlatamab in a patient with medullary thyroid carcinoma after progression on selpercatinib. Thyroid. 2026;36(6):682\u2013687. https:\/\/doi.org\/ 10.1177\/10507256261448706","DOI":"10.1177\/10507256261448706"},{"key":"ref178","doi-asserted-by":"crossref","unstructured":"179.\tMoura MM, Cavaco BM, Pinto AE, Leite V. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab. 2011;96(5):E863-E868. https:\/\/doi.org\/10.1210\/jc.2010-1921","DOI":"10.1210\/jc.2010-1921"},{"key":"ref179","doi-asserted-by":"crossref","unstructured":"180.\tHayes AR, Crawford A, Al Riyami K, et al. Metastatic medullary thyroid cancer: the role of 68Gallium-DOTA-somatostatin analogue PET\/CT and peptide receptor radionuclide therapy. J Clin Endocrinol Metab. 2021;106(12):e4903\u2013e4916. https:\/\/doi.org\/10.1210\/clinem\/dgab588","DOI":"10.1210\/clinem\/dgab588"},{"key":"ref180","doi-asserted-by":"crossref","unstructured":"181.\tMaghsoomi Z, Emami Z, Malboosbaf R, Malek M, Khamseh ME. Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review. BMC Cancer. 2021;21(1):579. https:\/\/doi.org\/10.1186\/s12885-021-08257-x","DOI":"10.1186\/s12885-021-08257-x"},{"key":"ref181","doi-asserted-by":"crossref","unstructured":"182.\tCunha LL, Ward LS. Translating the immune microenvironment of thyroid cancer into clinical practice. Endocr Relat Cancer. 2022;29(6):R67-R83. https:\/\/doi.org\/10.1530\/erc-21-0414","DOI":"10.1530\/ERC-21-0414"},{"key":"ref182","doi-asserted-by":"crossref","unstructured":"183.\tMulligan LM. GDNF and the RET receptor in cancer: new insights and therapeutic potential. Front Physiol. 2018;9:1873. https:\/\/doi.org\/10.3389\/fphys.2018.01873","DOI":"10.3389\/fphys.2018.01873"},{"key":"ref183","doi-asserted-by":"crossref","unstructured":"184.\tCastellone MD, Melillo RM. RET-mediated modulation of tumor microenvironment and immune response in multiple endocrine neoplasia type 2 (MEN2). Endocr Relat Cancer. 2018;25(2):T105-T119. https:\/\/doi.org\/10.1530\/ erc-17-0303","DOI":"10.1530\/ERC-17-0303"},{"key":"ref184","doi-asserted-by":"crossref","unstructured":"185.\tBongiovanni M, Rebecchini C, Saglietti C, et al. Very low expression of PD-L1 in medullary thyroid carcinoma. Endocr Relat Cancer. 2017;24(6):L35-l38. https:\/\/doi.org\/10.1530\/erc-17-0104","DOI":"10.1530\/ERC-17-0104"},{"key":"ref185","doi-asserted-by":"crossref","unstructured":"186.\tShi X, Li CW, Tan LC, et al. Immune co-inhibitory receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in medullary thyroid cancers: a large cohort study. J Clin Endocrinol Metab. 2021;106(1):120\u2013132. https:\/\/doi.org\/10.1210\/clinem\/dgaa701","DOI":"10.1210\/clinem\/dgaa701"},{"key":"ref186","doi-asserted-by":"crossref","unstructured":"187.\tWusiman D, Guo L, Li L, et al. Clinicopathological and prognostic significance of PD-L1 and TIM-3 expression in medullary thyroid carcinoma: a retrospective immunohistochemistry study. J Endocrinol Invest. 2024;47(1):91\u2013100. https:\/\/doi.org\/10.1007\/s40618-023-02126-z","DOI":"10.1007\/s40618-023-02126-z"},{"key":"ref187","doi-asserted-by":"crossref","unstructured":"188.\tPozdeyev N, Erickson TA, Zhang L, et al. Comprehensive immune profiling of medullary thyroid cancer. Thyroid. 2020;30(9):1263\u20131279. https:\/\/doi.org\/10.1089\/thy.2019.0604","DOI":"10.1089\/thy.2019.0604"},{"key":"ref188","doi-asserted-by":"crossref","unstructured":"189.\tBi Y, Ren X, Bai X, et al. PD-1\/PD-L1 expressions in medullary thyroid carcinoma: clinicopathologic and prognostic analysis of Chinese population. Eur J Surg Oncol. 2019;45(3):353\u2013358. https:\/\/doi.org\/10.1016\/j.ejso.2018.10.060","DOI":"10.1016\/j.ejso.2018.10.060"},{"key":"ref189","doi-asserted-by":"crossref","unstructured":"190.\tDel Rivero J, Donahue RN, Mart\u00e9 JL, et al. A case report of sequential use of a yeast-CEA therapeutic cancer vaccine and anti-PD-L1 inhibitor in metastatic medullary thyroid cancer. Front Endocrinol. 2020;11:490. https:\/\/ doi.org\/10.3389\/fendo.2020.00490","DOI":"10.3389\/fendo.2020.00490"},{"key":"ref190","doi-asserted-by":"crossref","unstructured":"191.\tHensel JA, Khattar V, Ashton R, Ponnazhagan S. Recombinant AAV-CEA tumor vaccine in combination with an immune adjuvant breaks tolerance and provides protective immunity. Mol Ther Oncolytics. 2019;12:41\u201348. https:\/\/ doi.org\/10.1016\/j.omto.2018.12.004","DOI":"10.1016\/j.omto.2018.12.004"}],"container-title":["Drugs in Context"],"original-title":[],"link":[{"URL":"https:\/\/www.drugsincontext.com\/wp-content\/uploads\/2026\/08\/dic.2026-4-3.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T09:56:22Z","timestamp":1788170182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.drugsincontext.com\/how-to-manage-medullary-thyroid-carcinoma-current-treatment-strategies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":191,"URL":"https:\/\/doi.org\/10.7573\/dic.2026-4-3","relation":{},"ISSN":["1740-4398","1740-4398"],"issn-type":[{"value":"1740-4398","type":"print"},{"value":"1740-4398","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"dic.2026-4-3"}}